Entia, founded in 2015, is a UK-based innovator in healthcare, focusing on revolutionizing cancer care through remote patient monitoring technology. The company is renowned for its slogan: "Unlocking the full potential of cancer therapy with at-home blood monitoring."
Entia provides oncology services that enhance treatment efficacy by predicting and preventing adverse effects, notably with the world’s first at-home full blood count analyzer. Their solutions help in early risk identification, allowing for timely interventions that extend treatment durations, reduce unexpected hospital admissions, and potentially improve survival outcomes.
The company collaborates with some of the world’s premier oncology centers and aids in advancing blockbuster therapies from leading industry figures. In its most recent financial milestone, Entia secured a £16.00M Series A investment on July 26, 2023, with significant contributions from Parkwalk Advisors and Business Growth Fund. Entia's trajectory showcases its potential as a pivotal player in the healthcare and medical devices industries.